MDAI
5,6-methylenedioxy-2-aminoindane
Viewing r1 — May 3, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
MDAI (5,6-methylenedioxy-2-aminoindane) — sparkle, mindy — is a synthetic empathogen of the aminoindane class. It is a rigid cyclic structural analog of MDA, designed to retain entactogenic warmth while eliminating neurotoxicity. MDAI is a serotonin-preferential monoamine releasing agent, producing its effects by triggering carrier-mediated serotonin and norepinephrine efflux with negligible dopamine activity.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
MDMA, MDA, 6-APB +3 moreMDMA, MDA, 6-APB, 5-MAPB, 5-APB, methylone show less
Synthesized by David Nichols at Purdue University in 1990 as a tool compound for studying entactogen pharmacology without serotonergic damage,[2] MDAI remained a laboratory curiosity until approximately 2007, when it appeared on European recreational markets. Uptake accelerated after the UK scheduling of mephedrone in 2010, and it was widely sold as a legal alternative.[3]
Subjective effects include emotional warmth, empathy enhancement, prosocial feelings, and mild mood elevation. The experience is characteristically gentle — MDMA-like emotional openness without the stimulant push or compulsive redosing urge, strongly amplified in social settings and often perceived as underwhelming when taken alone.[4] Nausea during onset, post-acute mood dip, and mild blood pressure elevation are common unsought effects.[5]
No physical dependence has been documented, and no confirmed fatalities from MDAI alone exist — all reported deaths involved polydrug combinations with other serotonergic substances.[6][7] The primary risk is serotonin syndrome when combined with other serotonergic drugs, a danger that scales with the number and potency of co-administered agents. A single non-blinded human study (N = 6) and one rodent toxicology paper constitute nearly the entire evidence base.[5][8]
History[edit]
Discovery
MDAI was first synthesized and characterized in 1990 by David Nichols and colleagues at Purdue University, appearing as "compound 3a" in the Journal of Medicinal Chemistry.[2] The research program aimed to create MDMA-like compounds that would retain empathogenic effects while eliminating the serotonergic neurotoxicity observed with MDMA and MDA. The design strategy constrained MDA's flexible side chain into a rigid indane ring — and it worked: at doses where MDMA depleted serotonin markers in rat brain, MDAI produced no measurable damage.[2]
From laboratory to legal high
MDAI remained an obscure research tool for seventeen years. Around 2007, it appeared on European recreational markets,[6][3] but uptake was modest until April 2010, when the UK banned mephedrone. The regulatory vacuum drove immediate demand for legal alternatives, and MDAI — marketed under street names including "sparkle" and "mindy" — filled the gap.[3] Its reputation as "non-neurotoxic," derived from the single 1990 Nichols paper, became a significant marketing asset in online drug communities.[3]
Scheduling and present status
The first UK deaths involving MDAI were reported in 2011–2012,[6] all in polydrug contexts. National scheduling followed on a piecemeal basis: China acted earliest (September 2010), individual US states followed (Minnesota 2012, Louisiana 2013), and the UK's blanket Psychoactive Substances Act covered MDAI from 2016.[9] As of 2026, MDAI carries no international UN scheduling and remains available through some online vendors in unregulated jurisdictions.[10]
The name "MDAI" follows standard phenethylamine abbreviation conventions: MD for methylenedioxy, AI for aminoindane. Street names "sparkle" and "mindy" emerged during the 2010–2012 UK legal high era. The compound was also sold in combination products — most notably "Pink Panthers," which contained MDAI blended with 2-aminoindane.[11] MDAI's cultural identity was shaped almost entirely by its positioning as a legal MDMA substitute: it was marketed on the promise of Nichols's non-neurotoxicity finding, a single data point that became the compound's entire brand.
Chemistry[edit]
Structure
MDAI belongs to the aminoindane family — compounds built on an indane ring (a cyclopentane fused to a benzene ring) with an amine group attached. The aminoindane scaffold is essentially a rigid version of the phenethylamine backbone: the flexible side chain found in amphetamines is locked into a five-membered ring, restricting its ability to rotate. MDAI adds a methylenedioxy bridge across the aromatic ring, making it a direct structural analog of MDA with a constrained side chain.[2]
Related compounds in the aminoindane series include 5-IAI (5-iodo-2-aminoindan),[12] 2-aminoindane (2-AI), and the N-methylated variant MMAI. The methylenedioxy bridge — shared with MDMA and MDA — is the key structural feature driving serotonergic activity.
Molecular properties
| Molecular formula | C₁₀H₁₁NO₂ |
| Molecular weight | 177.20 g/mol |
| XLogP | 1.2 |
The moderate lipophilicity (XLogP 1.2) indicates adequate penetration of the blood-brain barrier.[5] The hydrochloride salt melts at 256–275°C and is typically encountered as a white to off-white crystalline powder.[13]
Stereochemistry
MDAI has one chirality center at the amine-bearing carbon of the indane ring. All published research and commercial material uses the racemic mixture. No data exist on pharmacological differences between the (R)- and (S)-enantiomers — a notable gap given the well-documented enantioselectivity of structurally related amphetamines.
Structure-activity relationships
The rigid indane ring is the key innovation: by constraining MDA's side chain into a cyclic system, Nichols eliminated the neurotoxic potential while retaining MDMA-like behavioral effects in animals.[2] The methylenedioxy bridge is essential for serotonergic activity in this series — removing it (as in plain 2-aminoindane) dramatically reduces potency. The follow-up compound 5-IAI demonstrated that other aromatic substitutions (iodo in place of methylenedioxy) also produce non-neurotoxic entactogens, confirming the aminoindane scaffold itself as the protective element.[12]
Pharmacology[edit]
Mechanism of action
MDAI is a substrate-type monoamine releasing agent. Rather than blocking reuptake (as antidepressants do), it enters neurons through monoamine transporters and forces stored neurotransmitters out into the synapse — the same basic mechanism used by MDMA and the amphetamines.[1]
The defining feature is its selectivity profile: MDAI releases serotonin and norepinephrine powerfully but has very weak dopamine activity.[1][14] The gap between serotonin and dopamine potency is roughly 42-fold, placing MDAI deeper into the "pure entactogen" zone than MDMA itself.[14] This explains why it feels empathogenic without the stimulant push or compulsive redosing drive.
Direct receptor binding is negligible — MDAI does not activate serotonin receptors directly. Its effects come entirely from flooding the synapse with the brain's own serotonin and norepinephrine.[1]
Neurotoxicity profile
The original 1990 study found that MDAI did not damage serotonin neurons in rats at doses where MDMA caused significant depletion.[2] This "non-neurotoxic" label has been widely cited, but it rests on a single acute-dose rodent experiment. No replication studies, chronic dosing studies, or human neuroimaging data have been published. The characterization remains provisional.
Pharmacokinetics
Human pharmacokinetic data come from a single study of six participants who self-administered approximately 3 mg/kg orally (180–228 mg).[5] MDAI was first detected in blood around 20 minutes after ingestion, consistent with the reported onset of subjective effects. Detection in serum persisted for at least 4 days and in urine for at least 6 days — longer than typical MDMA detection windows.[5] No formal half-life has been calculated.
Rat data show rapid brain penetration (peak at 30 minutes) with a brain-to-blood ratio of approximately 4, confirming strong CNS access.[8] MDAI also accumulated in lung tissue at concentrations exceeding brain levels[8][4] — the clinical significance of this is unknown.
No data exist on which liver enzymes metabolize MDAI. By structural analogy to MDMA (which shares the methylenedioxy bridge), CYP2D6 involvement is predicted but unconfirmed.
Neuroscience[edit]
Where it acts
MDAI's serotonin-releasing activity is predicted to engage the same neural circuits as MDMA: reduced amygdala threat reactivity (lowering fear and social defensiveness), activation of oxytocin pathways from the posterior pituitary (enhancing prosocial bonding), and modulation of prefrontal-limbic connectivity (enabling emotional openness without cognitive overwhelm). Prolactin and cortisol elevation confirmed in human subjects are consistent with strong serotonergic neuroendocrine activation.[5] No MDAI-specific neuroimaging has been published.
Entactogenic window
Entactogens produce their characteristic prosocial effects within a pharmacological window defined by high serotonin activity relative to dopamine. MDAI sits deeper in this window than MDMA[1] — predicting purer empathogenic effects with less euphoric stimulation. This framework explains user reports of MDAI as "MDMA without the push"[4]: the emotional warmth is present, but the dopaminergic drive that makes MDMA feel urgent and compulsive is largely absent.
Several puzzles remain unresolved. Rats show hyperthermia at standard doses,[8] while human subjects showed no temperature increase at comparable doses[5] — the reason for this species discrepancy is unknown. Whether the (R)- and (S)-enantiomers differ in potency has never been tested. The lung accumulation observed in rats raises questions about potential pulmonary effects with repeated use,[8] and whether chronic MDAI exposure could cause cardiac valve damage (as seen with other serotonergic drugs) has not been assessed.
Subjective Effects[edit]
MDAI produces a characteristically gentle entactogenic state — emotional warmth, empathy, and prosocial openness unfold gradually without the stimulant urgency or jaw-clenching physical intensity of MDMA. The experience is strongly context-dependent: social settings amplify the empathogenic quality markedly, while solitary use often feels subtle or underwhelming. Higher doses deepen emotional openness and body warmth without dramatically shifting the qualitative character — there is no "breakthrough" threshold in the way psychedelics escalate.
Relative to MDMA, the experience occupies a gentler, quieter register — comparable emotional depth at adequate doses, but with less euphoric push, less physical activation, and substantially less compulsive quality.[4] The shorter duration (3–5 hours versus MDMA's 4–6) and absence of heart rate elevation in human data[5] reinforce the impression of a softer pharmacological profile.
Effect Grid
At common doses (approximately 100–175 mg oral), the full entactogenic experience emerges: pronounced emotional openness, empathy enhancement, feelings of closeness and connection with others, and a warm, content mood state. Music enhancement is marked. The experience is described as MDMA-like but with less stimulant "push" — a gentler, more purely empathogenic quality.
Physically, blood pressure elevation is expected based on human data at this range. Pupil dilation is pronounced. Bruxism (jaw clenching), mild nausea on onset, and slight temperature sensitivity are possible. Heart rate and body temperature were not elevated in the only controlled human study at this dose range.
Peak effects last 1–2 hours, with total subjective duration of 3–5 hours. Sleep is unlikely for at least 4–5 hours post-ingestion.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual haze / noise · Color enhancement · Visual acuity enhancement · Tracers
Sedation · Spontaneous body sensations · Tactile euphoria · Appetite suppression · Bruxism · Sexual arousal suppression · Physical fatigue · Excessive sweating · Dehydration sensation · Tingling / electric sensations · Dry mouth · Muscle relaxation · Bodily heaviness · Nausea · Increased urination · Dizziness · Headache · Pain suppression · Wakefulness
Bruxism · Sexual arousal suppression · Physical fatigue · Excessive sweating · Dehydration sensation · Tingling / electric sensations · Dry mouth · Muscle relaxation · Bodily heaviness · Nausea · Increased urination · Dizziness · Headache · Pain suppression · Wakefulness
Cognitive fatigue · Introspection enhancement · Aesthetic enhancement · Cognitive impairment · Thought deceleration · Motivation suppression · Focus suppression · Humor enhancement · Information processing suppression · Confusion
Thought deceleration · Motivation suppression · Focus suppression · Humor enhancement · Information processing suppression · Confusion
Irritability · Anhedonia · Catharsis
Emotional susceptibility · Communication enhancement
Timeline
First alerts appear 20–60 minutes after ingestion: a subtle shift in mood, faint bodily warmth, and mild restlessness. MDAI was first detected in serum approximately 20 minutes post-dose.
Building warmth, emerging emotional openness, and increasing sociability. Mild nausea or stomach discomfort may occur during this phase. Pupil dilation becomes apparent.
Full entactogenic effects: emotional warmth, empathy, music enhancement, and feelings of closeness. Blood pressure is elevated. Unlike MDMA, heart rate and body temperature are not typically increased.
Effects remain present but gradually diminish in intensity. Emotional openness and sociability persist. Physical stimulation wanes, and a gentle contentment replaces the peak intensity.
Gradual return to baseline. Residual warmth and mild mood elevation may linger. Fatigue begins to set in as serotonin stores are transiently depleted.
Residual mood changes may persist for hours to a day. Some individuals report a gentle afterglow; others experience low mood and fatigue consistent with transient serotonin depletion.
⚠ Do not drive or operate machinery for the remainder of the day following MDAI use, as residual cognitive and psychomotor impairment may persist beyond subjective awareness of effects.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- None
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Low
- Cross-tol.
- MDMA · MDA · 6-APB
Toxicity
No confirmed human fatalities from MDAI as the sole substance have been documented. All reported deaths involved combinations with other serotonergic drugs.[6][7][15] The mechanism of death in both animal toxicology and at least one human case involved disseminated intravascular coagulopathy (uncontrolled blood clotting) with brain swelling.[8][15]
Oral administration carries a substantially wider safety margin than injection. In rats, all animals survived 40 mg/kg oral while the same dose injected subcutaneously killed 90% within 15 minutes.[8] Typical human oral doses (100–300 mg, or 1.5–5 mg/kg) fall below the dose at which all rats survived orally, though direct species comparison is unreliable.
Liver toxicity
Laboratory screening classified MDAI among the most toxic compounds tested to human liver cells — exceeding MDMA, mephedrone, and methylone in cell damage.[16] No human liver injury cases have been reported, and the clinical significance remains uncertain, but pre-existing liver impairment increases theoretical risk.
Temperature regulation
MDAI caused overheating in group-housed rats, with the effect amplified by crowded conditions.[8] Human subjects showed no temperature increase under controlled conditions.[5] The discrepancy is unresolved — crowded, hot environments (clubs, festivals) may unmask hyperthermic risk not apparent in clinical settings.
Blood disorders
A case of methaemoglobinaemia (reduced oxygen-carrying capacity of blood) was reported in a user of "Pink Panthers," a product containing MDAI and 2-aminoindane.[11] Benzocaine contamination likely contributed.
Psychological risks
No systematic data on MDAI-specific psychological harms exist. By pharmacological class, acute anxiety, confusion, and agitation are expected at high doses. Serotonin syndrome — agitation, overheating, muscle rigidity, and rapid heart rate — was implicated in the earliest UK deaths[6] and observed at all doses in rat behavioral tests.[8]
Post-acute mood depression ("comedown") is expected from temporary serotonin depletion, though severity and duration have not been characterized for MDAI specifically.
Tolerance and dependence
No physical dependence has been documented. Tolerance is presumed to develop through depletion of serotonin stores — an inherently self-limiting mechanism, as the drug requires stored serotonin to produce its effects. Repeated dosing within a short window is expected to yield diminishing returns rather than escalating use.
Mice showed conditioned place preference (indicating the drug is reinforcing) across a range of doses.[17] However, the very weak dopamine activity predicts substantially lower abuse liability than stimulants.[14] Cross-tolerance with MDMA and other entactogens is assumed but unconfirmed.
Drug interactions
The central danger with MDAI is serotonergic combination. Every documented fatality involved co-administration with other serotonin-active substances.
Serotonergic substances: Co-use with other serotonin releasers (MDMA, benzofurans like 5-MAPB/5-APB/5-EAPB, other aminoindanes) produces additive serotonin flooding. The Belgium fatality involved simultaneous exposure to four serotonergic compounds.[7] The Zurich case involved MDAI with 2-MAPB.[15]
MAOIs: Absolute contraindication. An MAOI prevents breakdown of the serotonin that MDAI releases, creating sustained extreme serotonin levels — a textbook pathway to lethal serotonin syndrome.
Tramadol: Classified as a lethal combination. Tramadol inhibits serotonin reuptake and has weak releasing properties, creating clear mechanistic risk for serotonin syndrome.safety citation needed
Contraindications
MAOI use is an absolute contraindication. Concurrent use of other serotonergic substances (SSRIs, SNRIs, other entactogens, serotonergic psychedelics) represents a relative-to-absolute contraindication depending on specific agents and doses.[6][7][15]
Pre-existing heart conditions are a relative contraindication: MDAI elevates blood pressure[5] and releases norepinephrine, producing cardiovascular stress.[14]
Liver impairment is a relative contraindication based on the strong laboratory hepatotoxicity signal.[16]
History of psychotic disorders or seizure disorders: serotonin releasing agents can precipitate episodes, and MDAI disrupted sensorimotor gating at all tested doses in rats.[8]
Pregnancy and breastfeeding: no data exist, but exposure is contraindicated for any centrally active monoamine releaser.
Harm Reduction[edit]
Forms & Identification
MDAI is most commonly encountered as a white to off-white crystalline powder in hydrochloride salt form. Combination products (notably "Pink Panthers" containing MDAI + 2-aminoindane) have been documented,[11] meaning labeled MDAI products may contain additional active compounds. The purity and composition of unregulated MDAI cannot be assumed from appearance alone — reagent testing confirms identity but not purity or the absence of adulterants.
Given that all documented fatalities involved serotonergic polydrug combinations, confirming what is actually in a sample is the single most consequential harm reduction step for this substance.
Guidelines
- Test substance identity with reagent kits before use
- Start with a low dose and wait at least 90 minutes before considering redosing — onset can be gradual
- Avoid combining with any other serotonergic substance (other empathogens, SSRIs, MAOIs, tramadol)
- Stay hydrated but do not overdrink — sip water rather than consuming large volumes
- Maintain access to cool environments and fresh air, particularly in club or festival settings
- Have a sober companion present, particularly at higher doses or first experiences
- Allow at least 4–6 weeks between uses to permit serotonin recovery
- Do not redose repeatedly in a single session — diminishing returns from serotonin depletion increase adverse effects without proportionally increasing desired effects
Set & Setting
MDAI's effects are strongly context-dependent. Social, comfortable environments amplify the empathogenic quality; solitary or understimulating settings often produce underwhelming results. Physical setting matters: crowded, hot environments may increase overheating risk based on animal data showing socially-augmented hyperthermia.[8] A familiar, temperate environment with trusted company represents the lowest-risk context.
Aftercare & integration. The post-experience period typically involves mild mood dip from temporary serotonin depletion. Prioritize sleep, nutritious food, and gentle social contact in the 24–48 hours following use. Physical exercise can be resumed after adequate rest but avoid intense exertion on the day following use.
The empathogenic quality of MDAI may bring forward emotional material worth processing. If the experience surfaced difficult feelings or memories, journaling or a conversation with a trusted person can help integrate insights. Persistent low mood beyond 3–5 days warrants professional attention.
Recovery & Support
MDAI's weak dopamine activity means compulsive use patterns are less likely than with stimulants, but psychological habituation to the emotional state is possible with frequent use. If use has become a regular coping mechanism for social anxiety or emotional numbness, this signals a pattern worth examining.
Peer support communities and harm reduction organizations can provide non-judgmental guidance. Professional support is appropriate when use frequency escalates, when sober social functioning deteriorates, or when the post-use mood dip extends into persistent depression.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Signs that require immediate help include uncontrollable muscle rigidity or jerking, extremely high body temperature (skin hot to touch), seizures, confusion progressing to loss of consciousness, and blue-tinged lips or skin. These may indicate serotonin syndrome or cardiovascular crisis — both are medical emergencies.
Immediate steps:
- Call emergency services immediately
- Move the person to a cool, quiet area
- Remove excess clothing to help cool them
- Place in the recovery position if unconscious but breathing
- Do not give food or drink to an unconscious person
- Do not restrain someone having seizures — clear the area around them
What to tell the dispatcher: Name the substance (MDAI/aminoindane), approximate amount taken, time of ingestion, any other substances used, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from prosecution for drug-related emergencies.
Legal Status[edit]
MDAI carries no international scheduling under the United Nations drug conventions.[10] Regulatory control has proceeded through national legislation on a jurisdiction-by-jurisdiction basis, with substantial variation in classification severity.
In the United States, MDAI is not federally scheduled, though the Federal Analogue Act may apply when the compound is intended for human consumption — its structural relationship to MDA (Schedule I) makes it potentially subject to prosecution as a "substantially similar" substance. Individual states have moved independently: Louisiana and Minnesota have both placed MDAI in Schedule I.[9]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International | No control | Not scheduled under UN drug conventions[10] |
| United States (federal) | Unscheduled | Federal Analogue Act may apply; Louisiana Schedule I (June 2013); Minnesota Schedule I (August 2012)[9] |
| United Kingdom | Psychoactive Substances Act 2016 | Supply and production prohibited; personal possession not an offence[18] |
| China | Category I psychotropic | Controlled since September 2010[9] |
| Finland | Controlled | Banned December 2014 under NPS regulation[4] |
| Denmark | Controlled | Scheduled September 2015[4] |
| EU (multiple states) | Controlled | Cyprus, Czech Republic, Estonia, Hungary, Italy, Lithuania, Portugal, Sweden[4] |
| Canada | Not specifically scheduled | No specific scheduling confirmed[9] |
| Australia | Unknown | Not confirmed in available sourcescitation needed |
| Germany | Unknown | Not confirmed in available sourcescitation needed |
references
- [1]
- [2]
- [3] ^abcdGallagher CT, Assi S, Stair JL, Fergus S, Corazza O, Corkery JM, Schifano F (2012) 5,6-Methylenedioxy-2-aminoindane: from laboratory curiosity to 'legal high'. — Human Psychopharmacology doi:10.1002/hup.1255
- [4]
- [5] ^abcdefghijAngerer V, Schmid Y, Franz F, Gnann H, Speer JM, Gnann A, Helmecke S, Buchwald A, Brandt SD, Passie T, Liechti ME, Auwärter V (2024) Acute psychotropic, autonomic, and endocrine effects of 5,6-methylenedioxy-2-aminoindane (MDAI) compared with 3,4-methylenedioxymethamphetamine (MDMA) in human volunteers: A self-administration study. — Drug Testing and Analysis doi:10.1002/dta.3622
- [6]